ライフサイエンスコーパス: screen to identify

1 A screen to identify intergenic mutations that allow for sss1(t

2 We developed a screen to identify miRNAs that regulate liver repopulation af

3 Here, we conducted a high-throughput siRNA-based screen to identify genes that regulate HIF2alpha's transcript

4 We have previously used a bioinformatic screen to identify two interferon-stimulated genes (ISG) with

5 Here, we utilized a chemical screen to identify molecules that affect MCC ontogeny in the

6 Here we performed a high-content screen to identify drugs that block tumor cell extravasation

7 role of SGs in pathophysiology, we performed a high-content screen to identify small molecules that alter SG properties i

8 d regularly insterspaced short palindromic repeats (CRISPR) screen to identify mitochondrial genes necessary for the grow

9 d short palindromic repeats (CRISPR) interference (CRISPRi) screen to identify a minimal set of genes required for rapid

10 In this study, we used a genetic enhancer screen to identify apum23-4, a mutant allele of the ribosome

11 for ATP binding to ULK4, perform a virtual and experimental screen to identify small-molecule binders of ULK4, and identi

12 Here, we performed a genome-wide CRISPR loss-of-function screen to identify Foxp3 regulators in mouse primary Treg cel

13 We conducted a loss-of-function screen to identify genes required for the activity of alpha i

14 VID-19, we performed a genome-scale CRISPR loss-of-function screen to identify host factors required for SARS-CoV-2 viral

15 Here, we report an antiviral necroptosis-based genetic screen to identify novel host cell factors required for infec

16 Here, we used a chemical genetic screen to identify endothelial-specific direct substrates of

17 In a previous study, we established a forward genetic screen to identify genes required for multicellular developme

18 Using an unbiased genome-wide genetic screen to identify mutations affecting an FTD-ALS-related phe

19 Here, we employ a haploid screen to identify sulfated glycosaminoglycans (sGAGs) as its

20 We devised a modified yeast 3-hybrid screen to identify mutations that confer recognition of an 8-

21 Here we used a genome-wide CRISPR-interference screen to identify the reduced folate carrier SLC19A1, a fola

22 he present study, we perform a genome-scale CRISPR knockout screen to identify cellular host factors that restrict AAV in

23 enome-scale ORF overexpression screen and a CRISPR knockout screen to identify modulators of resistance to each inhibitor

24 We performed a whole-genome CRISPR-based knockout (KO) screen to identify genes important for cells to survive ER-ba

25 Here we performed an in vivo anti-miR screen to identify the miRNA drug targets within the miR-17~9

26 liana) CCS52A2-deficient plants in a suppressor mutagenesis screen to identify APC/C(CCS52A2) substrates or regulators, r

27 approach, starting with a high-throughput in vitro primary screen to identify inhibitors, building in silico models to c

28 Herein, we used a proteomic screen to identify lung macrophage proteins that form adducts

29 this, we performed a coimmunoprecipitation-based proteomics screen to identify proteins associated with Nod factor recept

30 We performed a small interfering RNA screen to identify targets for cutaneous squamous cell carcin

31 We performed a high-throughput whole-genome RNAi screen to identify novel inhibitors of ciliogenesis in normal

32 nge nuclear morphology, we conducted a high-throughput RNAi screen to identify epigenetic regulators that are required to

33 ated early in disease and may prove useful as a first round screen to identify individuals at risk of developing AD.

34 We devised a sensitized screen to identify natural metabolites capable of regulating

35 In a transposon-insertion sequencing screen to identify mutants synthetically lethal with a defect

36 In this work, we conducted a siRNA screen to identify genes of the DNA damage response/DNA repai

37 ental clinical drug SRA737 in an unbiased large-scale siRNA screen to identify novel mediators of CHK1 inhibitor sensitiv

38 We developed a high-throughput screen to identify compounds approved by the US Food and Drug

39 We therefore used a high-throughput screen to identify compounds that slowed growth in an MscL-de

40 Nevertheless, we performed a small molecule high-throughput screen to identify IL-36 antagonists using a novel TR-FRET bi

41 l known epigenetic proteins and performed a high-throughput screen to identify key candidates whose downregulation can de

42 We previously conducted a high-throughput screen to identify metabolic pathways that affect T3SS expres

43 We developed a high-throughput screen to identify miRNAs that regulate hepatocyte repopulati

44 In response, we developed a high-throughput screen to identify substrates of P-gp from a series of chemic

45 We therefore designed a high-throughput screen to identify such compounds.

46 ential scanning fluorimetry was used in a medium-throughput screen to identify six small molecules that interact with the

47 of risk-based screening (sensitivity, 82%; number needed to screen to identify 1 HCV case, 15) and birth cohort screening

48 Here, we used a transposon screen to identify a membrane protein complex that spatially

49 Here, we use a genome-wide screen to identify genes required for natural transformation

50 (2020) demonstrate the first viral-mediated, genome-wide screen to identify neuroprotective genes in wild-type and Hun